#Diabetes

Eli Lilly's Orforglipron Hits Primary Endpoints in Phase 3 ACHIEVE-4 Trial

Eli Lilly's oral GLP-1 drug orforglipron demonstrates significant cardiovascular safety and efficacy in phase 3 trials, showing a 16% lower risk of…

Eli Lilly Shares Rally as EloraTZP Data Shows 23.3% Weight Loss in Phase 2b

Eli Lilly's EloraTZP trial results show a 23.3% average weight loss, signaling a potential new benchmark in the company's obesity and type…